We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genes Linked to Drug Resistance in Testicular Cancer

By LabMedica International staff writers
Posted on 03 Feb 2015
Several new genetic mutations have been revealed that could drive testicular cancer. More...
In addition, a gene has been identified, which may contribute to tumors becoming resistant to current treatments.

The main testicular germ cell tumor (TGCT) histologies are seminomas, which resemble undifferentiated primary germ cells, and non-seminomas, which show differing degrees of differentiation. Cure rates for TGCTs are generally high, due to the sensitivity of malignant testicular germ cells to platinum-based chemotherapies; however this is at the cost of an increased risk of metabolic syndrome, infertility and secondary cancer.

A team of scientists led by those at the Institute of Cancer Research (London, UK) used a genetic technique called whole-exome sequencing to examine tumor samples from 42 patients with undergoing testicular cancer treatment. Surgical specimens were snap frozen within 30 minutes of surgery and matched blood samples were collected at the time of surgery. Tumor samples were trimmed to remove surrounding normal tissue, and tumor cells were confirmed by histological assessment. Tumor and matched lymphocyte DNA were extracted by standard techniques.

Samples for whole-exome sequencing were quantified using Qubit technology (Invitrogen; Carlsbad, CA, USA) and sequencing libraries constructed from 50 ng of respective normal/tumor DNA. Library preparation was performed using 37 Mb Nextera Rapid Capture Exome kits (Illumina; San Diego, CA, USA), with enzymatic tagmentation, indexing polymerase chain reaction PCR, clean-up, pooling, target enrichment and post-capture PCR amplification/quality control performed in-house, following standardized protocols. Samples underwent paired-end sequencing using the Ilumina HiSeq2500 platform with a 100-bp read length.

The investigators uncovered a number of new chromosome duplications and other abnormalities that could contribute to the development of this cancer, as well as confirming a previous association with the V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog gene (KIT). Their study also found defective copies of a DNA repair gene called X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 2 (XRCC2) in a patient who had become resistant to platinum-based chemotherapy. They were able to verify the link between XRCC2 and platinum resistance by sequencing an additional sample from another platinum-resistant tumor.

Clare Turnbull, MD, PhD, the team leader, said, “Our study is the largest comprehensive sequencing study of testicular tumors published to date, describing their mutational profile in greater detail than has been possible using previous technologies. We have identified new potential driver mutations for this type of cancer, and provided new evidence of a link between mutations in the gene XRCC2 and platinum treatment-resistant tumors.” The study was published on January 22, 2015, in the journal Nature Communications.

Related Links:

The Institute of Cancer Research
Invitrogen 
Illumina



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.